ArticleJournal of inherited metabolic disease2025
Impaired Proteostasis is Linked to Neurological Pathology in a Zebrafish NGLY1 Deficiency Model.
Article in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural history of NGLY1 deficiency: motor function & clinical features.Human molecular genetics · 2026Article
- NGLY1 as an Emerging Critical Modulator for Neurodevelopment and Pathogenesis in the Brain.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
NGLY1 is a key enzyme in the process of misfolded protein deglycosylation. Bi-allelic pathogenic variants in NGLY1 cause N-glycanase deficiency, also known as congenital disorder of deglycosylation (NGLY1-CDDG). This rare and multisystem autosomal recessive disorder is linked to a variable phenotype of global developmental delay, neuromuscular abnormalities, and alacrima, and it lacks effective treatment. We have studied the possible underlying mechanisms for the neuromuscular and ophthalmic phenotypes in an ngly1-deficient zebrafish model carrying a similar genetic variant that has also been identified in previously reported patients. We investigated phenotypic, biochemical, and molecular details underlying ngly1 deficiency using a zebrafish model. ngly1-deficient zebrafish phenotypes were characterized using histological staining, transmission electron microscopy (TEM), and micro-CT imaging. Furthermore, fish brain molecular and biochemical characterization was performed by gene expression analysis and immunoblotting techniques. Impaired proteostasis was evident in the brain of the mutant zebrafish, including accumulation of poly-ubiquitinated proteins and amyloid fibril aggregation. The mutant fish featured neuromuscular abnormalities and significant aquaporin1-protein reduction in the eyes and brain. The zebrafish model of NGLY1 deficiency provides an ideal platform for studying the molecular and biochemical mechanisms underlying NGLY1-CDDG in humans. Our novel findings of impaired protein homeostasis encompassing amyloid fibril aggregation (folding) and poly-ubiquitinated protein accumulation (degradation) in the brains of mutant zebrafish offer new insights into the brain pathology associated with NGLY1 deficiency. These discoveries may also advance our understanding of other neurodegenerative disorders and facilitate the identification of potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.